SLC7A6OS and neoplasm: The congruency of results observed with IWR-1 and p140Cap expression in TuBo cells in vitro and in vivo strongly argues that pharmacological interventions that stabilize the β-Catenin destruction complex, as exemplified by the use of IWR-1 in naïve TuBo cells, might represent an additional therapeutic strategy to selectively interfere with the β-Catenin/TIC/G-CSF/PMN-MDSCs axis, thereby restoring an efficient immune response to prevent tumor progression and metastasis.